Nausea was reported by 44% of adults taking Wegovy 2.4 mg across three placebo controlled trials of 2116 patients, against 16% on placebo. On Zepbound the figures were 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, against 8% on placebo, pooled from two trials of 2519 patients. Both sets come from the adverse reactions tables in the manufacturers own prescribing information.
The second number is the one worth holding onto. Nausea led only 1.8% of Wegovy patients to stop treatment, compared with 0.2% on placebo. It is the most common thing these drugs do to people and one of the least common reasons they quit.
- Wegovy 2.4 mg: nausea in 44% versus 16% on placebo. Zepbound: 25% to 29% depending on dose, versus 8% on placebo.
- Nausea caused treatment discontinuation in 1.8% of Wegovy patients and gastrointestinal events generally in 1.9% to 4.3% of Zepbound patients by dose.
- Both labels say the four week escalation steps exist specifically to reduce gastrointestinal reactions, and both report that most of these events happen during escalation and fall off afterwards.
- The trials recorded how many people had nausea, not how many days it lasted, so there is no published median duration to quote.
- By week 20 on semaglutide 2.4 mg, one trial found no evidence of delayed gastric emptying, while appetite suppression was still clearly present.
How often nausea is reported, by drug and dose
These rates come from the adverse reactions sections of the current US labels, which pool the pivotal weight management trials. The populations differ: 19% of the pooled Wegovy patients had type 2 diabetes and 25% of the pooled Zepbound patients did, and the pools are not the same trials. Read down the columns rather than comparing the two drugs across them.
| Drug and dose | Trial pool | Nausea | Placebo in the same pool |
|---|---|---|---|
| Wegovy (semaglutide) 2.4 mg | 3 trials, 2116 patients, up to 68 weeks | 44% | 16% |
| Zepbound (tirzepatide) 5 mg | 2 trials, 2519 patients, up to 72 weeks | 25% | 8% |
| Zepbound (tirzepatide) 10 mg | Same pool | 29% | 8% |
| Zepbound (tirzepatide) 15 mg | Same pool | 28% | 8% |
Notice that nausea did not climb with the Zepbound dose. It was slightly higher at 10 mg than at 15 mg. Vomiting did rise step by step, from 8% to 11% to 13%, and constipation moved the other way, from 17% down to 11%. Gastrointestinal events as a whole were reported by 56% of patients at all three Zepbound doses against 30% on placebo, so the overall burden was flat across doses even as the weight loss rose with them.
Fuller lists of what each trial logged are in our write ups of semaglutide side effects and tirzepatide side effects.
Why these drugs cause nausea
The usual one line explanation is that GLP-1 drugs slow the stomach down. That is part of it, and it is less settled than it sounds.
A dedicated 20 week trial in 72 adults with obesity measured gastric emptying directly, using paracetamol absorption after a standard breakfast (PMID 33269530). At week 20 on semaglutide 2.4 mg, the area under the paracetamol curve over five hours was 8% higher than placebo, which was statistically significant until the researchers corrected for the weight participants had lost, after which it was not. There was no effect at all on the first hour, on peak concentration or on time to peak. The authors concluded there was no evidence of delayed gastric emptying at week 20.
What the same trial did find was a large effect on eating. Energy intake at a free access lunch was 35% lower than placebo, hunger and prospective food consumption fell, fullness and satiety rose, and participants reported better control of eating and weaker food cravings. Body weight was down 9.9% against 0.4% on placebo.
Put those together and the picture is a receptor effect on the brain regions that regulate appetite and nausea, with a gastric component that is most plausible early on, while the dose is still rising, and that appears to settle by the time someone has been on a maintenance dose for a month. The mechanism itself is covered in more depth in how semaglutide works.
When it peaks
Both labels are explicit that the escalation schedule exists for this reason. Wegovy instructs prescribers to follow the four week steps to reduce the risk of gastrointestinal adverse reactions, and Zepbound says the same about its 2.5 mg increments. The Zepbound label then states directly that the majority of nausea, vomiting and diarrhoea events occurred during dose escalation and decreased over time.
That makes the escalation calendar a reasonable map of when people report feeling worst, which is the week or two after each step up rather than a steady state.
| Weeks | Wegovy dose | Zepbound dose |
|---|---|---|
| 1 to 4 | 0.25 mg | 2.5 mg |
| 5 to 8 | 0.5 mg | 5 mg |
| 9 to 12 | 1 mg | 5 mg or 7.5 mg |
| 13 to 16 | 1.7 mg | Up to 10 mg |
| 17 onward | 1.7 mg or 2.4 mg maintenance | Up to 15 mg maximum |
The Wegovy column is a fixed schedule in the label. The Zepbound column is not: after the first four weeks at 2.5 mg and the move to 5 mg, the label allows increases of 2.5 mg at a time after at least four weeks on the current dose, so where somebody is at week 12 depends on what their prescriber decided. If dose steps are new to you, the first weeks are described in what the first month on a GLP-1 looks like.
How long it lasts
This is the question with the weakest evidence behind it, and it is worth saying so plainly rather than inventing a number. The pivotal trials reported how many participants experienced nausea, not how many days each episode ran. There is no published median duration for Wegovy or Zepbound nausea to cite.
What the sources do support is two things. STEP 1 described nausea and diarrhoea as typically transient, mild to moderate in severity, and subsiding with time (PMID 33567185). The Zepbound label reports that most gastrointestinal events clustered in the escalation period and decreased afterwards, and that patients who stopped because of them mostly did so in the first few months.
So the honest answer to how long nausea lasts on Zepbound is that trial data points to days rather than months after a given dose step, and to the escalation phase rather than the maintenance phase, without pinning a figure to it.
When nausea is not just nausea
Both labels carry warnings about acute pancreatitis and gallbladder disease, and both tell patients to contact their prescriber about severe or persistent abdominal pain, which may be accompanied by vomiting. Persistent vomiting also matters because of dehydration and kidney injury, which the labels list under warnings. Nausea that is severe, that does not settle, or that comes with abdominal pain radiating to the back is a reason to speak to a prescriber rather than to wait it out.
Nothing in this article is a basis for changing, splitting, delaying or stopping a dose. Both labels leave those decisions with the prescriber, including the option in each one of holding an escalation step longer if a dose is not tolerated.
Does phentermine cause nausea?
Phentermine comes up alongside these drugs often enough to be worth a straight answer, and it is a different class: a sympathomimetic amine, taken daily, and indicated in its label only as a short term adjunct of a few weeks.
Its label does not list nausea among its gastrointestinal adverse reactions. What it lists is dryness of the mouth, unpleasant taste, diarrhoea, constipation and other gastrointestinal disturbances. That last phrase is doing a lot of work, and the label is an older one that carries no frequency table at all, so there are no percentages to compare with the 44% and 25% above. Dry mouth, not nausea, is the gastrointestinal complaint its label names first.
FAQ
How common is nausea on a GLP-1?
In the pooled weight management trials behind the labels, 44% of adults on Wegovy 2.4 mg reported nausea against 16% on placebo, and 25% to 29% of adults on Zepbound reported it depending on dose, against 8% on placebo.
How long does nausea last with Zepbound?
The trials did not publish a duration, only how many people were affected. The Zepbound label states that most nausea, vomiting and diarrhoea occurred during dose escalation and decreased over time, which points to the weeks after each dose step rather than the whole course of treatment.
Does nausea get worse at higher doses?
Not in the Zepbound data. Nausea was 25% at 5 mg, 29% at 10 mg and 28% at 15 mg, and overall gastrointestinal events were 56% at all three doses. Vomiting did increase with dose, from 8% to 13%.
Is it true that these drugs slow your stomach down?
Partly, and the best measurement is less dramatic than the claim. At week 20 on semaglutide 2.4 mg, a trial using paracetamol absorption found no evidence of delayed gastric emptying once body weight loss was accounted for, while appetite suppression and a 35% drop in energy intake at a test meal were clearly present.
How many people stop treatment because of nausea?
Nausea was the reason for discontinuation in 1.8% of Wegovy patients versus 0.2% on placebo. For Zepbound, gastrointestinal events of all kinds led 1.9%, 3.3% and 4.3% of patients at 5 mg, 10 mg and 15 mg to stop, against 0.5% on placebo.
Does phentermine cause nausea?
Its label does not name nausea. The gastrointestinal reactions it lists are dryness of the mouth, unpleasant taste, diarrhoea, constipation and other gastrointestinal disturbances, with no frequencies given, and phentermine is labelled for short term use of a few weeks.
Sources
- WEGOVY (semaglutide) prescribing information, sections 6.1 Clinical Trials Experience and 14 Clinical Studies. Novo Nordisk, via DailyMed.
- ZEPBOUND (tirzepatide) prescribing information, sections 6.1 Adverse Reactions, 12.2 Pharmacodynamics and 14.1 Clinical Studies. Eli Lilly and Company, via DailyMed.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). *N Engl J Med*. 2021;384(11):989-1002. PMID: 33567185
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). *N Engl J Med*. 2022;387(3):205-216. PMID: 35658024
- Friedrichsen M, Breitschaft A, Tadayon S, et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. *Diabetes Obes Metab*. 2021;23(3):754-762. PMID: 33269530
- Phentermine hydrochloride tablets prescribing information, sections 1 Indications and Usage and 6 Adverse Reactions, via DailyMed.
This article is for information only and is not medical advice. Dosing, suitability and any change to treatment are decisions for your prescriber.